Novo Nordisk Company Profile

Sr. No.

Item

Description

1

Company Name

Novo Nordisk A/S

2

Website

www.novonordisk-us.com

3

Established Date

1923

4

Headquartered

Denmark

5

Market Position/ History

Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and Rare diseases. The company was established in 1923 and is headquartered in Denmark. In the 1930s, Novo and Nordisk each established diabetes hospitals in Denmark to provide specialized diabetes care. In 1951, Nordisk’s foundation was established in the 1920s and Novo followed. Thereafter in 1969s, Novo opened a production plant in Kalundborg, Denmark. Then in 1985, the comapny launched NovoPen, the first insulin pen device. In 2019, a major breakthrough that further expanded treatment options and reduced barriers, this innovative tablet eliminates the need for injections with GLP-1 – a welcome relief for many people living with type 2 diabetes.

6

Sales Area

Worldwide

7

Manufacturing Location

16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia and US).

10 research and development centres in five countries (China, Denmark, India, UK and US).

8

No. of Employees

~64,319 (as of December 2023)

9

Competitors

• GSK plc
• Vivus LLC
• Currax Pharmaceuticals LLC
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Boehringer Ingelheim International GmbH
• Arena Pharmaceuticals Ltd
• Eisai Co., Ltd.
• Rhythm Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.

10

CEO

Lars Fruergaard Jørgensen

11

Ownership Type

Public

12

Contact Inform

Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and rare diseases. The company has a presence in over 170 countries. The company has 10 research and development centers in five countries (China, Denmark, India, the UK, and the US), and 16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia, and US).

Novo Nordisk operates in two business segments based on therapies: Diabetes and Obesity care and Rare disease, representing the entirety of the Group's operations. ation

Novo Alle 1 2880 Bagsværd Denmark

Tel: +45-4444-8888

Product

Description

Saxenda (liraglutide) injection 3 mg

Saxenda and SaxendaCare are registered trademarks of Novo Nordisk A/S

• SAXENDA is an injectable prescription medicine used for adults with obesity or overweight (excess weight) who also have weight-related medical problems, and children aged 12 to 17 years with a body weight above 132 pounds (60 kg) and obesity to help them lose weight and keep the weight off.
• SAXENDA should be used with a reduced-calorie diet and increased physical activity.
• SAXENDA and VICTOZA have the same active ingredient, liraglutide, and should not be used together or with other GLP-1 receptor agonist medicines.
• It is not known if SAXENDA is safe and effective when taken with other prescription, over-the-counter medicines, or herbal weight loss products.
• It is not known if SAXENDA is safe and effective in children under 12 years of age.
• It is not known if SAXENDA is safe and effective in children aged 12 to 17 years with type 2 diabetes.

Wegovy (semaglutide) injection 2.4 mg

Wegovy Prescribing Information, including Boxed Warning

Wegovy is a registered trademark of Novo Nordisk A/S.

• WEGOVY is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity:
• To reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
• That may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.
• WEGOVY contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
• It is not known if WEGOVY is safe and effective for use in children under 12 years of age.

Year

Latest News

February 2024

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

Novo Nordisk announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.

August 2023

Novo Nordisk strikes $11bn deal to expand production of weight loss drug Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s valuation beyond $500bn.

The group reported record sales for 2023, driven by surging demand for its diabetes and anti-obesity drugs Ozempic and Wegovy. However, Novo Nordisk warned that supply chain bottlenecks were hampering its ability to produce enough of the best-selling treatments.